<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045848</url>
  </required_header>
  <id_info>
    <org_study_id>Biofreedom V2.2</org_study_id>
    <nct_id>NCT03045848</nct_id>
  </id_info>
  <brief_title>Biofreedom Prospective Multicenter Observational Registry</brief_title>
  <official_title>Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of Biofreedom Stent in Patients With Coronary Artery Disease (Biofreedom Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wonju Severance Christian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LEADERS-FREE trial demonstrated the safety and efficacy of polymer-free drug-coated stent
      (Biofreedom, Biosensors International Technologies, Singapore) in patients with high bleeding
      risk. But, there are limited clinical evidences for extending these findings to generalized
      patients who are eligible to PCI. Therefore, the purpose of this registry is to evaluate the
      safety and efficacy of Biofreedom stent in patients with coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) and related interventional cardiology field are
      rapidly growing in current era. First generation drug eluting stent (DES) needed long-term
      dual antiplatelet therapy (DAPT) for preventing future stent thrombosis. But, second
      generation DES showed better clinical outcomes in terms of target lesion revascularization
      and stent thrombosis. Later, polymer technology that was used to release drugs gradually
      improved. BASKET-PROVE II trial compared biodegradable polymer (BP) DES (Nobori, Terumo) with
      durable polymer DES (Xience Prime, Abbott Vascular) and bare metal stent (ProKinetik,
      Biotronik) for the safety and efficacy in 2-year follow-up. BP-DES showed 7.6% of event rates
      in composite endpoint including cardiac death, myocardial infarction (MI), clinically
      indicated target-vessel revascularization (TVR) which was non-inferior to DP-DES(6.8%) and
      superior to bare metal stent (12.7%). There were no statistical differences for the event
      rates of stent thrombosis, MI and cardiac death among three groups in 1-year follow-up.
      Biodegradable polymer has begun to emerge and suggested the possibility of shortening the
      duration of DAPT. LEEDERS-FREE trial was designed to confirm the safety and efficacy of
      polymer-free drug-coated stent (Biofreedom, Biosensors International Technologies, Singapore)
      compared to bare metal stent (Gazelle stent, Biosensors International Technologies,
      Singapore) in patients with high bleeding risk. During 390 days, drug coated stent showed
      significant superiority to bare metal stent for the safety composite endpoint (cardiac death,
      MI or stent thrombosis) (9.4% vs. 12.9%, P=0.0005). Clinically-driven target-lesion
      revascularization also showed significant differences between drug-coated stent (5.1%) and
      bare metal stent (9.8%) (P&lt;0.001). This results provided new therapeutic options that DAPT
      duration could be shortened to 1 month in patients with high bleeding risk. The rate of
      cardiovascular events was relatively higher than second generation DES. However, this result
      should be carefully interpreted because the main purpose of LEADERS-FREE trial is to enroll
      high bleeding risk patients who are generally excluded in second generation DES studies.
      Additional studies are needed because there are limited clinical evidences for extending
      these findings of LEADERS-FREE trial to generalized patients who are eligible to PCI.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Device-oriented composite end point (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, any myocardial infarction not clearly attributable to a nontarget vessel, and clinically indicated target-lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite end point</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of any death, any myocardial infarction, and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction not clearly attributable to a non-target vessel</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target-lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target-vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease Aggravated</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Biofreedom drug-coated stent</arm_group_label>
    <description>Subject implanted Biofreedom DCS for coronary artery disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biofreedom drug-coated stent</intervention_name>
    <description>BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.</description>
    <arm_group_label>Biofreedom drug-coated stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All-comers patient population with all subjects requiring coronary revascularization with a
        drug-coated stent (DCS)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with â‰¥ 19 years

          -  Subject implanted with Biofreedom DCS within 1 month

          -  Subject who decided to participation and signed informed consent

        Exclusion Criteria:

          -  Known intolerance to heparin, aspirin, clopidogrel, biolimus, cobalt chromium or
             contrast media (Subject with hypersensitivity to contrast media controlled by steroid
             and pheniramine can be included this study, but subject with anaphylaxis to contrast
             media will be excluded).

          -  Pregnancy

          -  Woman who have a plan of pregnancy during study period

          -  Subject with life expectancy less than 12 months

          -  Subject with cardiogenic shock

          -  Subject treated with other drug-eluting stent (DES), bioresorbable vascular scaffold
             (BVS) or bare metal stent (BMS)

          -  Subject participating in other randomized controlled study with DES, BVS or BMS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junghan Yoon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junghan Yoon, MD, PhD</last_name>
    <phone>+82-33-741-1219</phone>
    <email>jyoon@yonsei.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun-Won Lee, MD</last_name>
    <phone>+82-33-741-1219</phone>
    <email>ljwcardio@yonsei.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kangwon National University School of Medicine</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon-do</state>
        <zip>200-722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byung-Ryul Cho, MD</last_name>
      <phone>+82-33-258-9226</phone>
      <email>heartcho@kangwon.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Byung-Ryul Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junghan Yoon, MD, PhD</last_name>
      <phone>+82-33-741-1219</phone>
      <email>jyoon@yonsei.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jun-Won Lee, MD</last_name>
      <phone>+82-33-741-1219</phone>
      <email>ljwcardio@yonsei.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Jun-Won Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung-Hwan Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung-Su Yoo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jang-Young Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min-Soo Ahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung-Gyun Ahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junghan Yoon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young-Jin Youn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung-Woo Son, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nae-Hui Lee, MD</last_name>
      <phone>+82-32-621-5437</phone>
      <email>naeheelee@naver.com</email>
    </contact>
    <investigator>
      <last_name>Nae-Hui Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-do</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tae Hoon Ahn, MD</last_name>
      <phone>+82-32-460-8385</phone>
      <email>encore@gilhospital.com</email>
    </contact>
    <investigator>
      <last_name>Tae Hoon Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-do</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung-il Woo, MD</last_name>
      <phone>+82-32-890-2445</phone>
      <email>wjswgs@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sungl-il Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic Kwandong University International St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-do</state>
        <zip>22711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Myung Gon Kim, MD</last_name>
      <phone>+82-32-290-3256</phone>
      <email>mkkimharu@naver.com</email>
    </contact>
    <investigator>
      <last_name>Myung Gon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13495</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Wook Kim, MD</last_name>
      <phone>+82-31-780-5852</phone>
      <email>swlim@cha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Wook Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>So-Yeon Choi, MD</last_name>
      <phone>+82-31-219-5712</phone>
      <email>sychoimd@outlook.com</email>
    </contact>
    <investigator>
      <last_name>So-Yeon Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joong-Hee Lee, MD</last_name>
      <phone>+82-53-620-3313</phone>
      <email>seranflute@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joong-Hee Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin-Bae Lee, MD</last_name>
      <phone>+82-53-650-4389</phone>
      <email>jblee@cu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jin-Bae Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <state>Gyeongsangnam-do</state>
        <zip>49267</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Busan</city>
        <state>Gyeongsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kook-Jin Chun, MD</last_name>
      <phone>+82-55-360-1454</phone>
      <email>ptca82@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kook-Jin Chun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inju University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <state>Gyeongsangnam-do</state>
        <zip>612-896</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doo-il Kim, MD</last_name>
      <phone>+82-51-797-3100</phone>
      <email>jo1216@inje.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Doo-il Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheju Halla General Hospital</name>
      <address>
        <city>Jeju</city>
        <state>Jeju-do</state>
        <zip>63127</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seung Ho Kang, MD</last_name>
      <phone>+82-64-740-5276</phone>
      <email>metronics@paran.com</email>
    </contact>
    <investigator>
      <last_name>Seung Ho Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inju University Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>01757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byung-Ok Kim, MD</last_name>
      <phone>+82-2-950-1214</phone>
      <email>byungokim@paik.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Byung-Ok Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Woon Choi, MD</last_name>
      <phone>+82-2-970-8203</phone>
      <email>cjw1108@eulji.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jae Woon Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KyungHee University at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin-Man Cho, MD</last_name>
      <phone>+82-2-440-6107</phone>
      <email>cardiocho@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jin-Man Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bum Ki Hong, MD</last_name>
      <phone>+82-2-2019-3311</phone>
      <email>bkhong@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Bum Ki Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang-Wook Kim, MD</last_name>
      <phone>+82-2-6299-1395</phone>
      <email>swivus@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sang-Wook Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Borame Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Hyun Kim, MD</last_name>
      <phone>+82-2-870-3864</phone>
      <email>shkimmd@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin-Won Kim, MD</last_name>
      <phone>+82-2-920-5797</phone>
      <email>kjwmm@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jin-Won Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Health Service Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chang Hoon Lee, MD</last_name>
      <phone>+82-2-2225-4141</phone>
      <email>zekilee@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Chang Hoon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wonju Severance Christian Hospital</investigator_affiliation>
    <investigator_full_name>Junghan Yoon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Observational registry</keyword>
  <keyword>All-comers open label registry</keyword>
  <keyword>Drug coated stent</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Stenting</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

